Considerations for Future Treatment of Inflammatory Skin Diseases: Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity
Symposium Date: Friday, November 18, 2016November 18, 2016 New York Academy of Medicine, New York, NY
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, November 18, 2017
Note: Credit Is No Longer Available
 | James G. Krueger, MD, PhD D. Martin Carter Professor in Clinical Investigation Head of Laboratory for Investigative Dermatology Co-director, Center for Clinical and Translational Science The Rockefeller University Hospital New York, NY |
 | Vjay K. Kuchroo, DVM, PhD Samuel L. Wasserstrom Professor of Neurology Harvard Medical School Director, Evergrande Center for Immunologic Diseases Harvard Medical School and Brigham and Women's Hospital Boston, MA |
 | Michael D. Rosenblum, MD, PhD Assistant Professor Department of Dermatology University of California San Francisco San Francisco, CA |
Co-provided by
Psoriasis occurs when T-cells become overly activated and attack healthy skin. This activation compromises the body’s normal state of immune tolerance, mistakenly recognizing the body’s own tissues as foreign. As long as the body is making activated T-cells, psoriasis will return. Improvement with current treatment is not permanent. Re-establishing immune tolerance—tolerance induction—can lead to sustained resolution of the autoimmunity. Ultimately, permanent remission may be dependent on treatments that reduce inflammation, decrease the number of activated T-cells, and inducing tolerance.
This 90-minute symposium features expert faculty presenting the latest evidence and information highlighting how tolerance induction can be integrated into treatment selection, how pathogenic T-cells may differentiate into regulatory T-cells (Tregs), and how the principles of disease interception apply to mechanisms of current and emerging treatments in psoriasis.
At the end of this CE activity, participants should be able to:
- Recognize the role of cutaneous Tregs in tolerance induction and as a therapeutic target in inflammatory skin diseases.
- Describe how pathogenic T-cells may transdifferentiate into regulatory T-cells.
- Illustrate how principles of disease interception apply to mechanisms of current and emerging treatments in psoriasis.
Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Novartis Pharmaceuticals Corporation.
Dermatologists, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare providers with an interest in psoriasis and psoriatic arthritis.
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
USF Health designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number:
0376-0000-16-032-L01-P
Type: knowledge-based
Successful completion of this CE activity includes participating in the live activity, reviewing the course materials, within 30 days of completion of the activity, and completing your activity evaluation and post-test online (75% pass rate required). You may print your certificate or statement of credit immediately. Please visit www.CMEOutfitters.com/20176 (requires free account activation).
Disclosure Declaration
It is the policy of USF Health and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. USF Health and CME Outfitters, LLC, have evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Krueger has disclosed that he has received research and grant support from Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Dermira, Inc.; Innovaderm Research Inc.; Janssen Pharmaceuticals, Inc.; Kadmon Corporation, LLC; Kyowa Hakko Kirin Co., Ltd.; LEO Pharma Inc.; Novartis; PAREXEL International Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and Vitae Pharmaceuticals, Inc. He serves as a consultant for AbbVie Inc.; Baxter; Biogen Idec; Boehringer Ingelheim; Bristol-Myers Squibb Company; Dermira, Inc.; Janssen Pharmaceuticals, Inc.; Kadman Corporation, LLC; Kineta, Inc.; Eli Lilly and Company, Merck & Co.. Inc.; Novartis; Pfizer Inc.; sanofi-aventis U.S. LLC; EMD Serono, Inc.; and XenoPort, Inc.
Dr. Kuchroo has disclosed that he has received research and grant support from NIH/National Institute of Neurological Disorders and Stroke (NINDS); NIH/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH/National Institute of Allergy and Infectious Diseases; Crohn's and Colitis Foundation of America; Guthy Jackson Charitable Foundation; and Sanofi/Genzyme Corporation.
Dr. Rosenblum has disclosed that he has received grant support from AbbVie Inc. and is a stock shareholder of Delinia, Inc.
Jeffrey Helfand, DO, MS (peer reviewer) has nothing to disclose.
Kimberley Murray, RN, MS (peer reviewer) has nothing to disclose.
Daniela V. DiBiase, MS (planning committee) has nothing to disclose.
Sharon Tordoff, CHCP (planning committee) has nothing to disclose.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MM-066-111816-90
